Back to Search
Start Over
Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody
- Source :
- Pediatric Allergy and Immunology. 27:446-451
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- Targeting the IgE pathway is a clinically validated strategy for treating IgE-mediated diseases. Omalizumab, an anti-IgE antibody, which binds to free IgE and prevents the binding of IgE to FcεRI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti-IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others. Anti-CεmX, which binds to membrane-bound IgE (mIgE) on IgE-switched B cells, lyses mIgE-expressing B lymphoblasts and prevents the allergen-induced generation of IgE-producing plasma cells, offers an alternative mechanism of intervening with the IgE inflammatory pathway. Because anti-CεmX does not bind to free IgE, it can modulate the IgE pathway regardless of the serum IgE levels in treated patients. These unique pharmacologic mechanisms potentially enable anti-CεmX to provide different clinical utilities from anti-IgE and serve as a therapeutic and a prophylactic in some IgE-mediated diseases, which are not adequately treated with current medicine.
- Subjects :
- 0301 basic medicine
Allergy
Urticaria
Immunology
Omalizumab
Antibodies, Monoclonal, Humanized
Immunoglobulin E
Lymphocyte Depletion
03 medical and health sciences
0302 clinical medicine
medicine
Animals
Humans
Immunology and Allergy
Immunosuppression Therapy
B-Lymphocytes
biology
business.industry
Antibody-Dependent Cell Cytotoxicity
Atopic dermatitis
medicine.disease
Rhinitis, Allergic
Asthma
030104 developmental biology
030228 respiratory system
Latex allergy
Pediatrics, Perinatology and Child Health
biology.protein
Antibody
Allergic bronchopulmonary aspergillosis
business
Anaphylaxis
medicine.drug
Subjects
Details
- ISSN :
- 09056157
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Pediatric Allergy and Immunology
- Accession number :
- edsair.doi.dedup.....fe214dfe01eb80d5d3435542bc594a40